HK:2162 Stock Latest News
Company AnnouncementsKeymed Biosciences Launches HK$100 Million Share Purchase for RSU Incentive Plan2w ago2162
Company AnnouncementsKeymed Biosciences’ Stapokibart Revenue Surges as China Clears New Adolescent Atopic Dermatitis Use1M ago2162
Company AnnouncementsKeymed Biosciences announces orderly resignation of non-executive director2M ago2162
Company AnnouncementsKeymed Biosciences updates board and committee structure2M ago2162
Company AnnouncementsKeymed Biosciences Signs Regional Licensing Deal for Stapokibart2M ago2162
Company AnnouncementsKeymed Biosciences Turns Profitable on Surging Drug Sales and BD Windfall2M ago2162Company AnnouncementsKeymed Biosciences Plans RMB Share Issue for Shanghai Sci-Tech Board Listing2M ago2162
Company AnnouncementsKeymed’s CM512 Hits Phase II Targets and Wins Breakthrough Status for Nasal Polyp Treatment3M ago2162
Company AnnouncementsKeymed Biosciences Sets Board Meeting to Approve 2026 Interim Results and Consider Dividend3M ago2162
Company AnnouncementsKeymed’s CLDN18.2 Drug CMG901 Delivers Phase III Survival Gain in Gastric Cancer3M ago2162
Company AnnouncementsKeymed’s CM512 Wins China Breakthrough Status, Advances in Multiple Phase II Trials3M ago2162
Company AnnouncementsKeymed Biosciences Swings to Profit on Kangyueda Surge and Licensing Windfall4M ago2162
Company AnnouncementsKeymed Biosciences Shareholders Approve All AGM Resolutions, Renew Capital Mandates4M ago2162Company AnnouncementsKeymed Biosciences Sets AGM to Approve Accounts, Board Changes and New Share Mandate6M ago2162
Company AnnouncementsKeymed Biosciences Details Gain and Capital Plans From Ouro Medicines Stake Disposal7M ago2162
Company AnnouncementsKeymed Biosciences boosts revenue on Kangyueda push while deepening R&D pipeline7M ago2162
Company AnnouncementsKeymed Biosciences to Realize Up to US$320 Million From Ouro Medicines Exit7M ago2162
Company AnnouncementsKeymed Biosciences Sets March 26 Board Meeting to Approve 2025 Results and Consider Final Dividend8M ago2162




